Brain serotonin 5-HT(1A) receptor binding in schizophrenia measured by positron emission tomography and [11C]WAY-100635.

BACKGROUND Results of postmortem studies show an elevation in serotonin-1A (5-hydroxytryptamine-1A [5-HT(1A)]) receptor density in the prefrontal and temporal cortices of patients with schizophrenia. This study examined 5-HT(1A) receptors in vivo in patients with schizophrenia using positron emission tomography and [carbonyl-(11)C]-N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-(2-pyridinyl)cyclohexane carboxamide ([(11)C]WAY-100635). METHODS The 5-HT(1A) binding potential of 14 antipsychotic drug-naïve patients with a DSM-IV diagnosis of schizophrenia was compared with that of 14 age-matched healthy controls. Positron emission tomography data were analyzed using 9 cortical regions of interest, which were delineated on a coregistered magnetic resonance image and transferred to the positron emission tomographic image, with the cerebellum as the reference region for a simplified reference tissue model. We also performed a voxel-wise comparison using statistical parametric mapping. RESULTS The region of interest-based analysis revealed a significant mean +/- SD cortical 5-HT(1A) receptor binding potential increase of 7.1% +/- 6.4% in patients with schizophrenia (F = 2.975; P =.02); local differences were +20% in the left medial temporal cortex (F = 9.339;P =.005) and +13% in the right medio temporal cortex (F = 4.453; P =.045). There were no significant differences in regional tracer delivery or cerebellar [(11)C]WAY-100635 uptake. The voxel-based analysis also confirmed a group difference in the left medial temporal cortex. CONCLUSIONS The biological significance of elevated 5-HT(1A) receptor density in schizophrenia remains unclear. Given the location of 5-HT(1A) receptors on pyramidal cells, this elevation may reflect an abnormal glutamatergic network. Our finding needs to be viewed in light of preclinical evidence supporting a role for 5-HT(1A) receptors in mediating antipsychotic action and extrapyramidal adverse effects of drugs.

[1]  Shitij Kapur,et al.  Serotonin 5-HT1A Receptor Binding Potential Declines with Age as Measured by [11C]WAY-100635 and PET , 2001, Neuropsychopharmacology.

[2]  J. Deakin,et al.  The 5-HT1A receptor in schizophrenia: a promising target for novel atypical neuroleptics? , 2001, Journal of psychopharmacology.

[3]  S. Houle,et al.  Imaging the 5-HT(1A) receptors with PET: WAY-100635 and analogues. , 2000, Nuclear medicine and biology.

[4]  R. Kikinis,et al.  Planum temporale and Heschl gyrus volume reduction in schizophrenia: a magnetic resonance imaging study of first-episode patients. , 2000, Archives of general psychiatry.

[5]  H. Meltzer,et al.  The effect of serotonin1A receptor agonism on antipsychotic drug-induced dopamine release in rat striatum and nucleus accumbens , 2000, Brain Research.

[6]  H. Meltzer,et al.  The effect of serotonin(1A) receptor agonism on antipsychotic drug-induced dopamine release in rat striatum and nucleus accumbens. , 2000, Brain research.

[7]  H. Meltzer.  The Role of Serotonin in Antipsychotic Drug Action , 1999, Neuropsychopharmacology.

[8]  Ralph Myers,et al.  Assessment of Spatial Normalization of PET Ligand Images Using Ligand-Specific Templates , 1999, NeuroImage.

[9]  B. Dean,et al.  No change in the density of the serotonin1A receptor, the serotonin4 receptor or the serotonin transporter in the dorsolateral prefrontal cortex from subjects with schizophrenia , 1999, Neurochemistry International.

[10]  Roger N. Gunn,et al.  Tracer Kinetic Modeling of the 5-HT1AReceptor Ligand [carbonyl-11C]WAY-100635 for PET , 1998, NeuroImage.

[11]  C. Halldin,et al.  Quantitative analyses of carbonyl-carbon-11-WAY-100635 binding to central 5-hydroxytryptamine-1A receptors in man. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[12]  Robert B. Innis,et al.  Development and Reliability of a Method for Using Magnetic Resonance Imaging for the Definition of Regions of Interest for Positron Emission Tomography. , 1998, Clinical positron imaging : official journal of the Institute for Clinical P.E.T.

[13]  C Burger,et al.  A JAVA environment for medical image data analysis: initial application for brain PET quantitation. , 1998, Medical informatics = Medecine et informatique.

[14]  Vincent J. Cunningham,et al.  Parametric Imaging of Ligand-Receptor Binding in PET Using a Simplified Reference Region Model , 1997, NeuroImage.

[15]  J. Joyce,et al.  Alterations in the cortical serotonergic system in schizophrenia: A postmortem study , 1997, Biological Psychiatry.

[16]  Christer Halldin,et al.  PET-characterization of [carbonyl-11C]WAY-100635 binding to 5-HT1A receptors in the primate brain , 1997, Psychopharmacology.

[17]  Paul J. Harrison,et al.  [3H]WAY–100635 for 5–HT1A receptor autoradiography in human brain: a comparison with [3H]8–OH–DPAT and demonstration of increased binding in the frontal cortex in schizophrenia , 1997, Neurochemistry International.

[18]  C. Katona,et al.  5-HT1A receptor binding sites in post-mortem brain samples from depressed suicides and controls. , 1997, Journal of affective disorders.

[19]  D L Hill,et al.  Automated three-dimensional registration of magnetic resonance and positron emission tomography brain images by multiresolution optimization of voxel similarity measures. , 1997, Medical physics.

[20]  A. Lammertsma,et al.  Simplified Reference Tissue Model for PET Receptor Studies , 1996, NeuroImage.

[21]  Paul J. Harrison,et al.  5-HT1A and 5-HT2A Receptor mRNAs and Binding Site Densities Are Differentially Altered in Schizophrenia , 1996, Neuropsychopharmacology.

[22]  E. Prinssen,et al.  Effects of dopamine antagonists in a two-way active avoidance procedure in rats: interactions with 8-OH-DPAT, ritanserin, and prazosin , 1996, Psychopharmacology.

[23]  Victor W. Pike,et al.  Remotely-controlled production of the 5-HT1A receptor radioligand, [carbonyl-11C]WAY-100635, via 11C-carboxylation of an immobilized Grignard reagent , 1996 .

[24]  K. Wȩdzony,et al.  Ipsapirone enhances the dopamine outflow via 5-HT1A receptors in the rat prefrontal cortex. , 1996, European journal of pharmacology.

[25]  J. Deakin,et al.  Autoradiography with [3H]8-OH-DPAT reveals increases in 5-HT1A receptors in ventral prefrontal cortex in schizophrenia , 1996, Biological Psychiatry.

[26]  H. Meltzer,et al.  Serotonin1A receptors are increased in postmortem prefrontal cortex in schizophrenia , 1996, Brain Research.

[27]  H. Praag,et al.  The role of serotonin in schizophrenia , 1995, European Neuropsychopharmacology.

[28]  D. Bowen,et al.  NMDA‐induced glutamate and aspartate release from rat cortical pyramidal neurones: evidence for modulation by a 5‐HT1A antagonist , 1995, British journal of pharmacology.

[29]  M. Huttunen.  The Evolution of the Serotonin‐Dopamine Antagonist Concept , 1995, Journal of clinical psychopharmacology.

[30]  A. Breier.  Serotonin, schizophrenia and antipsychotic drug action , 1995, Schizophrenia Research.

[31]  Karl J. Friston,et al.  Statistical parametric maps in functional imaging: A general linear approach , 1994 .

[32]  C. Dourish,et al.  Silent 5-HT1A receptor antagonists: utility as research tools and therapeutic agents. , 1993, Trends in pharmacological sciences.

[33]  J. Kleinman,et al.  Serotonin Uptake Sites and Serotonin Receptors Are Altered in the Limbic System of Schizophrenics , 1993, Neuropsychopharmacology.

[34]  S. Moncada.  Silent 5-HT A receptor antagonists: utility as research tools and therapeutic agents , 1993 .

[35]  Anat Biegon,et al.  Autoradiographic analysis of serotonin 5-HT1A receptor binding in the human brain postmortem: effects of age and alcohol , 1991, Brain Research.

[36]  橋本 健志.  Increase in serotonin 5-HT[1A] receptors in prefrontal and temporal cortices of brains from patients with chronic schizophrenia , 1991 .

[37]  C. Tanaka,et al.  Increase in serotonin 5-HT1A receptors in prefrontal and temporal cortices of brains from patients with chronic schizophrenia. , 1991, Life sciences.

[38]  S. Ahlénius.  Antipsychotic-like properties of the 5-HT1A agonist 8-OH-DPAT in the rat. , 1989, Pharmacology & toxicology.

[39]  R. Kahn,et al.  The role of serotonin in schizophrenia. , 1988, Schizophrenia bulletin.

[40]  S. Kay,et al.  The positive and negative syndrome scale (PANSS) for schizophrenia. , 1987, Schizophrenia bulletin.

[41]  M. Mintun,et al.  A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography , 1984, Annals of neurology.

[42]  B. Tabachnick,et al.  Using Multivariate Statistics , 1983 .